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Competitive Polymerase Chain Reaction to Estimate the Number of BCR-ABL Transcripts in Chronic Myeloid Leukemia Patients After Bone Marrow Transplantation
By Nicholas C.P. Cross, Lin Feng, Andrew Chase, Julie Bungey, Timothy P. Hughes, and John M. Goldman
We have developed a competitive polymerase chain reaction (PCR) titration assay that estimates the number of BCR-ABL transcripts in chronic myeloid leukemia patients to monitor minimal residual disease after bone marrow transplantation (BMT). The assay gave reproducible results and allowed differences in BCR-ABL message levels of half an order of magnitude to be distinguished. Of 91 patients studied by nonquantitative PCR, 28 who had a positive PCR result on at least one occasion posttransplant were analyzed by competitive PCR. Seventeen patients had no evidence in their marrow of cytogenetic relapse during the period of observation; BCR-ABL transcript numbers in these cases ranged from approximately 10 to 8001 pg RNA. Ten of the 11 patients who relapsed cytogenetically were studied when Philadelphia-positive metaphases were first detected in their marrow; transcript numbers
HRONIC MYELOID leukemia (CML) is character-
C ized in greater than 90% of cases by a translocation between the BCR gene on chromosome 22 and the ABL gene on chromosome 9, cytogenetically detectable by the presence of Philadelphia (Ph) chromosome. The novel chimeric fusion gene, p2 10 BCR-ABL, is expressed in approximately 95% of CML cases and expression of the reciprocal product, ABL-BCR derived from the 9q+ chromosome, is detected in approximately two-thirds of cases.' BCR-ABL mRNA can be specifically and efficiently detected by the polymerase chain reaction (PCR); because this fusion gene is leukemia-specific it can be used as a marker to identify residual disease after CML can be treated by allogeneic bone marrow transplantation (BMT). The probability of relapse for patients in first chronic phase (CP1) who receive unmanipulated marrow from an HLA-identical sibling donor after highdose chemoradiotherapy is 10% to 20% at 5 years. The outlook for patients receiving transplants in advanced phases of disease is worse and the leukemia-free survival for those undergoing BMT in blastic transformation is only 5% to 1 5%.5-7
We and others have found that residual CML cells are commonly detectable by PCR (PCR positive) for a number of monthsafter BMT in patients who are in complete cytogenetic remission, but in many cases the leukemia subsequently becomes undetectable (PCR negative).'-'' This finding suggests that PCR positivity early after transplant is of limited prognostic significance. Conversely, we have found in serial studies that patients persistently or intermittently PCR positive at or longer than 1 year post-BMT have a significantly greater rate of relapse than those individuals who remain PCR negative.* Thus, PCR positivity can be used to identify groups of individuals at elevated risk of relapse, but the test is not predictive for particular individuals. To define better the kinetics of relapse or cure after BMT for CML, we have developed a semiquantitative competitive PCR titration assay that provides an estimate of the number of residual BCR-ABL transcripts, and therefore, by ranged from 1,600 to 7 X 1 Os/pg RNA. Patients in hematologic relapse had between 9 X 1 O4 and 1 O6 BCR-ABL transcriptslpg RNA. Patients who progressed from cytogenetic remission to cytogenetic relapse and then to hematologic relapse had increasing numbers of BCR-ABL transcripts in their blood. Three patients had clear evidence of rising numbers of BCR-ABL transcripts before routine detection of cytogenetic relapse. Conversely patients without cytogenetic relapse generally had low or falling numbers of transcripts. We conclude that serial monitoring of residual disease post-BMT by estimating the number of BCR-ABL transcripts provides more information than conventional cytogenetics or nonquantitative PCR and may identify patients in need of therapeutic intervention before the onset of overt relapse. implication, the number of residual leukemia cells present in samples. PCR. Preparation of RNA from peripheral blood samples by ultracentrifugation, cDNA synthesis, and the two-step nested PCR procedure used for detection of BCR-ABL transcripts have been described previously. 8 The amount of RNA extracted was determined by the optical density at 260 nm. Usually 10 to 40 pgof RNA was recovered from 10 to 20 mL of peripheral blood leukocytes. Rigorous precautions were taken to avoid contamination of PCRs. Samples were processed in laminar flow hoods, plugged aerosol-resistant pipette tips were used at all stages, two negative controls were included in each run (one introduced at the RNA extraction step and one at cDNA synthesis), and all samples were processed in duplicate on separate days. Reaction products were electrophoresed on I .5% agarose gels in a separate room using dedicated pipettes. At no time during this study was contamination found in any of the negative controls. To ensure reproducible sensitivity of the assay, each run included a dilute positive RNA control (M5): cDNA was synthesized from 20 pg of RNA extracted from a mixture of K562
MATERIALS AND METHODS

Patients
and HL60 cells at a ratio of 1 to IO'. One-eighth of this cDNA was used for nested PCR. All results were discarded for any run if the M5 did not show an easily discemible b3a2 band.
Construction of competitor template. Plasmid pGD2 IO (kindly provided by G. Daley and R. van Etten) contains a full-length b3a2 BCR-ABL cDNA. After digestion with BamHl and Kpn I the I. Ikb junction fragment was isolated and subcloned into pEMBLl8 to yield plasmid pGDBK2. This subclone was digested with Bal I to excise a 100-bp fragment in ABL exon a2, dephosphorylated with calf intestinal phosphatase, and ligated to bacteriophage X DNA that had been cleaved with Hue Ill and A h I. After transformation into DH5, a clone, designated pBKXS, was selected that contained a X insert. DNA sequencing of this clone showed the insert to be 201 bp (Fig I) . After PCR with the second-step primers, the competitor yields a band of 559 bp compared with 458 bp and 383 bp for b3a2 and b2a2 transcripts, respectively. pBKX5 is 5.25 kb in size and therefore I ng equals 1. half order of magnitude on a logarithmic scale, ie, IO7, 3.2 X IO6, IO6, 3.2 X IO5, etc. Competitive PCR. Nested PCR was performed as described previously,8 except that 2.5 pL of cDNA plus 2.5 pL of competitor were added to 20 pL of first-step mix instead of 5 pL cDNA. Firststep PCRs were diluted 200-fold and I pL was used to seed the second step reaction. Samples were quantified initially at every order of magnitude and then again at every halforder of magnitude. The equivalence point at which the competitor and sample band would be of equal intensity was estimated independently by two individuals. This approach was found to be preferable to performing further competitive PCRs to determine an exact equivalence point because of the limited amount of cDNA that could be obtained from samples. Any discordance was resolved by performing the analysis for a third time and scoring the majority result. We found that only approximately 5% of duplicate results were discordant. Due to the size difference between the competitor and BCR-ABL, the number of molecules of competitor at the equivalence point was multiplied by 1.2 for b3a2 patients and 1.5 for b2a2 patients (the ratio in size of competitor and b3a2 or b2a2 PCR products, respectively) to derive the number of BCR-ABL molecules in the sample. This number was converted to the number of molecules per microgram of sample RNA.
Primer extension. Oligo I 8s-I (5' CCACAGTTATCCAAG-TGGGA 3') was designed to hybridize to the 18s RNA between positions 137 and 156." The oligo was end-labeled using polynucleotide kinase" and y-"P-ATP, and 20 ng was hybridized to 1 pg RNA in IX cDNA buffer (50 mmol/L Tris, pH 8.3, 75 mmol/L KCI, 3 mmol/L MgCI,) by cooling from 65°C to room temperature over a period of 30 minutes. Extension was performed at 37°C for 2 hours in IX cDNA buffer containing 10 mmol/L dithiothreitol (DTT), I mmol/L each of the four deoxynucleotides, 400 U Moloney murine leukemia virus (MMLV) reverse transcriptase, and 40 U RNasin. After adding an equal volume of formamide dyes, samples were heated to 80°C for 5 minutes and electrophoresed on 6% polyacrylamide sequencing gels." Gels were dried and exposed to autoradiographic film at -70°C for 16 hours.
RESULTS
Compelitive PCR lirralion assay. We engineered a plasmid construct to introduce an extm' DNA sequence between the primer sites used for PCR of BCR-ABL cDNA (Fig I) . Amplification of this clone, pBKX5, produces a larger product than either b2a2 or b3a2 BCR-ABL under identical conditions and the three are readily distinguishable after agarose gel electrophoresis. We have used this clone as a competitor in a PCR titration assay.14 Serial dilutions of linearized pBKX5 were added to fixed amounts of test cDNA and the mixture subject to standard two-step nested PCR. The competitor clone competed with the endogenous sample BCR-ABL for primers, enzymes, and nucleotides in the reaction. If the initial concentration of the competitor is much higher than that of sample fusion gene message, then only the competitor band is visible on the final gel. Conversely, if many fewer molecules of clone are added, then only the sample BCR-ABL band is visible. If the starting reaction contained equal numbers of molecules, then the gel showed both bands with the ratio of the fluorescence intensity between the two in proportion to their sizes. In this case, the competitor, b3a2, and b2a2 result in band sizes of 559 bp, 458 bp, and 383 bp, respectively. If, after titration, a number of competitor molecules is obtained that results in use only. competitor and sample bands of equal fluorescence intensity, then to derive the number of sample molecules the competitor number must be multiplied by 1.2 for b3a2 and 1.5 for b2a2. If the amount of RNA that was used for cDNA synthesis is known, this number can be converted to the number of BCR-ABL transcripts detected per microgram of RNA.
A number of experiments were performed to establish the accuracy and reproducibility of the competitive PCR titration assay.
First, serial dilutions of a sample of CML blood were made into normal blood and quantification performed to see if the number of BCR-ABL transcripts detected corresponded to the dilution factor. The equivalence point between the competitor and BCR-ABL in RNA derived from peripheral blood leukocytes of a patient in cytogenetic relapse after BMT was found to be between 3 X IO4 and lo5 molecules/ pg of total RNA (Fig 2) . Inspection of the intensity of the competitor and patient b2a2 PCR bands suggested a level of roughly 7 X IO4 competitor molecules and therefore 1.1 X IO' BCR-ABL molecules. Dilution of the CML blood 10-fold into normal blood resulted in a reduction of detectable BCR-ABL transcripts, with an equivalence in fluorescence intensity at roughly 7 X IO3 competitor molecules. Similarly, dilution of 100-and I ,000-fold results in equivalence points 100-fold and 1,000-fold less, respectively. This experiment establishes linearity of the assay over at least 4 orders of magnitude and shows that the competitor and BCR-ABL cDNA are amplified with equal efficiency.
To show the reproducibility of competitive PCR, cells Accuracy and reproducibility of the assay.
from a patient with CML in chronic phase were collected and divided into eight parts. RNA was extracted independently from each fraction and IO pg used for cDNA synthesis and quantitative PCR. The results are shown in Fig 3. In each of the eight samples A to G, the point at which the fluorescence intensity of the b3a2 and competitor bands would be equal can be seen to lie between 3 X lo5 and IO6 molecules of competitor added. The equivalence points were estimated to be 5 x lo', 7 x lo5, 5 x lo', 5 x IO', 4 x IO', 6 X IO', 5 X lo', and 6 X IO' (mean, 5.25 X IO'; standard deviation, 8.9 x lo4) molecules of competitor added, respectively. The standard deviation found here is only 17% of the mean and thus shows that results of the assay are reproducible. Estimation of BCR-ABL transcripts to within half an order of magnitude is therefore achievable because 95% of determinations fall within two standard deviations of the mean, assuming a normal distribution. Because the competitor is DNA and is therefore added to the first PCR, there is no direct control for the reverse transcription step. To see if this step was a significant source of variation, we routinely performed quantitative PCR on the M5 dilute positive RNA controls that had been reverse transcribed over a number of months using different batches of reverse transcriptase and other reagents (Fig 4) . Again, a high reproducibility between samples can be seen with fluorescence intensity equivalence points lying between 30 and 100 molecules of competitor added. This experiment shows that variation in the efficiency of cDNA synthesis, once conditions have been established, is low. Occasional instances of inefficient reverse transcription were found by failure of the M5 to produce a b3a2 band after nested PCR, in these cases, results from all samples in that batch were discarded. A potentially far greater source of variation is the quality of the sample RNA. We have used a primer extension assay to check for the integrity of the 18s RNA (Fig 5) Correlation het ween cvtogenetics and BCR-A BL levels. Having established the accuracy and reproducibility of the competitive PCR assay, we estimated the number ofdetectable BCR-ABL transcripts in 4 untreated chronic-phase patients. All had levels of between 5 X l Os and l O6 BCR-ABL transcripts/pg RNA. We proceeded to apply the assay to patients who were PCR positive after BMT. Results of patients in whom Ph-positive metaphases were found at some time after BMT are shown in Fig 6 and results of patients who remained in complete remission are shown in Fig 7. Patients who remained in complete remission generally had low levels of BCR-ABL transcripts and many had PCR positivity approaching the limit of detection at IO or less than IO molecules per microgram of RNA. In contrast, patients in whom Ph-positive metaphases were detected in the marrow had higher levels (Fig 8) . For example, IO patients who relapsed cytogenetically had contemporaneous PCR assays; all had greater than 1,600 BCR-ABL transcripts/pg RNA at the time that Ph-positive metaphases were first detected (range, 1.600 to 7 X IO5 transcripts/pg RNA). Three patients had BCR-ABL levels within this range, but no Ph chromosomes were found in the first 30 contemporaneous marrow metaphases examined. Specifically, patients no. I, 3, and 8 had 4,500,6,000, and 10.000 BCR-ABL transcripts detected at 6, 8, and 24 months post-BMT, respectively. In view of these relatively high levels, the cytogenetics slides were reexamined. For patient no. I, 0 of 52 metaphases were Ph positive; 2 of 50 were positive for patient no. 3 and 3 of 72 were positive for patient no. 8. Each ofthese patients were examined 3 to 4 months later; each had increased BCR-ABL levels and Ph-positive metaphases were detected in the first 30 evaluable cells examined. Cytogenetics slides were reevaluated in two further patients: patient no. 13 had 800 BCR-ABL transcripts/pg RNA at 3 months post-BMT and 0 of 3 1 Ph-positive metaphases; patient no. 7 had 500 BCR-ABL transcripts/pg RNA at 12 months post-BMT and 0 of 40 Ph-positive metaphases. In each case, there were no further evaluable metaphases. Therefore, the lowest BCR-ABL level at which Ph-positive metaphases were detected by routine cytogenetics (ie, 30 metaphases examined) was 1,600 transcripts/pg RNA and the highest level at which only cells of normal karyotype were found was 10.000 transcripts/pg RNA.
A total of 1 1 patients relapsed either cytogenetically or hematologically during this study. Ofthose who had serial semiquantitative PCR assays, all were found to have increasing numbers of detectable transcripts during progression from complete remission to cytogenetic relapse and finally to hematologic relapse. Patients no. l, 3, 6, and 10 had not relapsed clinically, and only a small minority of metaphases in these individuals are Ph positive. It will be of interest to see whether these patients progress to full hematologic relapse. Of the 7 patients who did proceed to hematologic relapse, patients no. 4,8, and 9 relapsed into chronic phase, no. 5 and 7 relapsed into accelerated phase, and no. 2 and 1 I relapsed into blast crisis. Relapse into accelerated phase or blast crisis appears to be a rapid process. Patients no. 7 and 1 I both showed dramatic increases in the level of BCR-ABL transcripts of 200-and 660-fold, respectively, over a period of 3 to 5 months, and patient no. 2 relapsed 2 months after a finding of only 200 BCR-ABL transcripts/pg RNA. However, relapse into chronic phase may proceed at a slower pace: transcript levels in patient no. 9 increased IO-fold and then IO-fold again over two 6-month periods, whereas relapse for patient no. In the remaining 8 cases, insufficient contemporaneous PCR and cytogenetics results were obtained to unambiguously detect an increase in transcript levels before relapse.
DISCUSSION
We have developed a competitive PCR titration assay that allows us to estimate the number of BCR-ABL transcripts present in samples from CML patients. The method is accurate and reproducible; we have derived a standard deviation of the assay and shown that differences in the level of BCR-ABL transcripts of half an order of magnitude can be distinguished. The variation in the reverse transcription step is generally low and can be effectively controlled for by routine quantification of a control sample, which means that a DNA, rather than an RNA, competitor can be used. This greatly simplifies the procedure and also has the advantage that the competitor is much less likely to deteriorate over long periods of time. The quality and amount of sample RNA is controlled by a primer extension assay. Although estimation of the equivalence point, currently performed by inspection, could be improved by direct densitometry from the agarose gels or by use of radioactive/ fluorescently labeled primers," we have aimed to keep the method as simple as possible and have shown that the variation thus obtained is acceptably low. Patients in untreated chronic phase showed a level of between 5 X IO5 and lo6 BCR-ABL transcripts per microgram of RNA. Assuming the peripheral blood of these patients to contain nearly 100% CML cells, and the average amount of RNA per cell to be 10 pg, then each cell would contain on average 5 to 10 copies of BCR-ABL mRNA. Several data points have been obtained in this study at about this level in patients after transplant, suggesting that single CML cells are being detected.
We and others have found that qualitative PCR assays are of limited predictive value for individual patients after BMT for CML.2,8-'o,L6 In particular, some patients are PCR positive for a number of months after transplant before becoming PCR negative. Although all patients are PCR positive before relapse, those who are persistently or intermittently PCR positive at or longer than I year after BMT have an increased probability, rather than a certainty, of relapse. We have shown here that competitive PCR effectively discriminates between those patients who have increasing numbers of BCR-ABL transcripts, and so may be in an early stage of relapse, and those who have decreasing or very low numbers of transcripts and therefore may be cured. For instance, patients no. 9 and 23 were both persistently PCR positive for 2 years after BMT. At 18 months after transplant, patient no. 23 had very low BCR-ABL levels (>lo BCR-ABL transcripts/pg RNA), whereas patient no. 9 had 3,500 transcriptslpg RNA. Six months later, patient no. 9 had relapsed and patient no. 23 was still PCR positive, but again at a very low level. Several patients who had very low BCR-ABL levels were PCR negative on subsequent testing. Of the I7 patients in complete remission, patients no. 22 and 25 had relatively high BCR-ABL levels of 100 and 150 transcripts/ pg RNA, respectively, at the most recent test. Patients no.
12 and I7 had low but increasing numbers of transcripts. All 4 will need to be observed closely by further PCR and cytogenetic analysis for signs of relapse. The 14 remaining patients all had very low or decreasing BCR-ABL levels, or had become PCR negative.
Three of three evaluable patients showed a clear increase in the number of BCR-ABL transcripts before the routine detection of Ph-positive metaphases in the marrow. Other patients who had serial assays showed increasing numbers of detectable transcripts in the progression from complete remission to cytogenetic relapse to hematologic relapse. To effectively predict relapse, PCR results would have to be obtained more frequently. We suggest that patients should be monitored routinely at 3, 6, 9, 12, 18, 24, etc. months post-BMT. If a patient converts from PCR negative to PCR positive, or shows increasing numbers of transcripts on sequential analyses, then assays should be performed at 1-to 2-monthly intervals.
Studies by other groups using selected patients also suggest that estimation of the number of BCR-ABL transcripts by either a dilution assayI6 or competitive PCR"," may be useful in determining which patients are likely to relapse. This study suggests that routine monitoring of CML patients after BMT by competitive PCR may effectively distinguish between those who will relapse and those who may be cured. It may soon be possible to consider therapeutic intervention, eg, donor bu@ coat i n f u~i o n '~,~~ or a-interferon, for such individuals before the development of overt relapse.
